Tokyo Tape
Sign in
← Sakai Chemical Industry

Half-year report · Q2

4078.TEDINET S100UO2I
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed

Amended by S100V7D8 (2025-02-07).

Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥41.9bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥82.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥2.6bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥2.6bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥3.1bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥2.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.8bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥121.2bnat 2024-09-30Cons.Assets
Total assets¥125.4bnat 2024-03-31Cons.Assets
Total assets¥131.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥44.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥50.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥77.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥75.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥14.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥16.6bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥14.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥7.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥6.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥3.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥4.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.712024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-437.652023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥97.232024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio59.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.2bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2024-04-01 → 2024-09-30¥38.4bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2024-04-01 → 2024-09-30¥37.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥798m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.8bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2024-04-01 → 2024-09-30¥4.4bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2024-04-01 → 2024-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥111m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2024-04-01 → 2024-09-30¥65m
—segment totalrevenue2024-04-01 → 2024-09-30¥42.8bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥41.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥910m
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.8bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 516
ItemContextValueUnit
Interest expenses paid ope cf fin cfPrior1YTDDuration-53000000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-67000000JPY
Income taxes paid ope cfPrior1YTDDuration-522000000JPY
Income taxes paid ope cfCurrentYTDDuration-513000000JPY
Income taxes refund ope cfPrior1YTDDuration307000000JPY
Income taxes refund ope cfCurrentYTDDuration221000000JPY
Paid for tender offer related expenses ope cfPrior1YTDDuration-342000000JPY
Paid for tender offer related expenses ope cfCurrentYTDDuration－JPY
Net cash provided by used in operating activitiesPrior1YTDDuration3187000000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration7420000000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-1646000000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-3693000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration0JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration2000000JPY
Purchase of investment securities inv cfPrior1YTDDuration-12000000JPY
Purchase of investment securities inv cfCurrentYTDDuration-7000000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration60000000JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration786000000JPY
Other net inv cfPrior1YTDDuration-27000000JPY
Other net inv cfCurrentYTDDuration-40000000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-1625000000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-2952000000JPY
Net increase decrease in short term loans payable fin cfPrior1YTDDuration-1191000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration-7002000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration4500000000JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration3000000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-1604000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-1833000000JPY
Proceeds from issuance of convertible bond type new stock reservation rights attached corporate bond fin cfPrior1YTDDuration3000000000JPY
Proceeds from issuance of convertible bond type new stock reservation rights attached corporate bond fin cfCurrentYTDDuration－JPY
Purchase of treasury stock fin cfPrior1YTDDuration-0JPY
Purchase of treasury stock fin cfCurrentYTDDuration-0JPY
Cash dividends paid fin cfPrior1YTDDuration-485000000JPY
Cash dividends paid fin cfCurrentYTDDuration-578000000JPY
Dividends paid to non controlling interests fin cfPrior1YTDDuration-33000000JPY
Dividends paid to non controlling interests fin cfCurrentYTDDuration-12000000JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfPrior1YTDDuration-2631000000JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfCurrentYTDDuration-150000000JPY
Other net fin cfPrior1YTDDuration35000000JPY
Other net fin cfCurrentYTDDuration－JPY
Net cash provided by used in financing activitiesPrior1YTDDuration1587000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-6578000000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration186000000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration268000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration3336000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-1841000000JPY
Cash and cash equivalentsPrior2YearInstant12188000000JPY
Cash and cash equivalentsPrior1YearInstant16475000000JPY
Cash and cash equivalentsPrior1QuarterInstant15524000000JPY
Cash and cash equivalentsCurrentQuarterInstant14633000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass